Gastroparesis

Quick definition. Gastroparesis means the stomach empties its contents too slowly. GLP-1 medications deliberately slow stomach emptying, so the term appears both as a side effect concern and in guidance about surgery and anesthesia.

What Gastroparesis Is

Gastroparesis literally means "stomach paralysis." It describes delayed gastric emptying — food lingering in the stomach far longer than normal — in the absence of any physical blockage. Typical symptoms include nausea, vomiting (sometimes of undigested food eaten hours earlier), early fullness after only a few bites, bloating, and upper-abdominal discomfort. In its established chronic form it is most commonly caused by long-standing diabetes damaging the vagus nerve, by certain surgeries, or by no identifiable cause at all.

Why It Matters for GLP-1 Users

Slowing gastric emptying is not an accidental side effect of GLP-1 receptor agonists — it is part of how they work. By holding food in the stomach longer, these drugs prolong fullness and blunt the post-meal blood sugar spike. The same mechanism, taken too far, produces the nausea, bloating, and early satiety that are the most common complaints during treatment. For most patients this delayed emptying is mild, dose-related, and tends to ease as the body adapts. It is generally most pronounced right after starting and after each dose increase.

Drug-Induced Slowing Versus Chronic Gastroparesis

It is important to separate the expected, usually reversible slowing caused by GLP-1 medications from true chronic gastroparesis as a disease. The drug effect typically improves with a slower titration schedule, smaller meals, and dose adjustment, and it resolves after stopping the medication. There have been reports of severe, persistent symptoms in some users, and gastroparesis is an area of ongoing study and litigation. Patients with pre-existing gastroparesis or severe gastrointestinal disease are generally advised to use these drugs with caution or avoid them.

The Anesthesia and Surgery Concern

Because food may remain in the stomach longer than expected, GLP-1 users undergoing procedures requiring sedation face a theoretical risk of aspirating stomach contents into the lungs. In 2023 the American Society of Anesthesiologists issued guidance suggesting patients consider holding daily GLP-1 doses on the day of a procedure and weekly doses the week before, and that anesthesia teams treat these patients as potentially having a "full stomach." Guidance in this area continues to evolve, so patients should always tell their surgical and anesthesia teams that they take a GLP-1 medication well ahead of any scheduled procedure.

Managing the Symptoms

When stomach-slowing symptoms appear during normal treatment, the standard approach is conservative: eat smaller and more frequent meals, favor lower-fat and lower-fiber foods that clear the stomach more easily, stay upright after eating, and maintain hydration. If symptoms are severe or persistent, a prescriber may pause escalation, step the dose back down, or reconsider the medication entirely. Severe or unrelenting vomiting, signs of dehydration, or intense abdominal pain warrant prompt medical attention rather than self-management.